Esperion Announces Positive CLEAR Outcomes Results To Be Pre

NEXLETOL (bempedoic acid) is the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint

Related Keywords

Mphil Cantab , Kausik Ray , Steven Nissen , Sheldon Koenig , Vascular Thoracic Institute At Cleveland Clinic , American College , Annual Scientific Session Together With , World Congress , Late Breaking Clinical Trial , Breaking Clinical Trial Presentation , Bempedoic Acid , Statin Intolerant Patients , High Cardiovascular Risk , Great Hall , Chief Academic Officer , Thoracic Institute , Cleveland Clinic , Expert Theatre , Next Step , Lowering Therapy , Oral Nonstatin Therapies , Late Breaking Clinical Trial Deep Dive , Prescribing Information ,